PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis
August 04, 2021 08:00 ET
|
PharmaTher Holdings Ltd.
Focusing on becoming a global leader in prescription-based ketamine productsAdvancing to a Phase 2 clinical study in the U.S. TORONTO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd....
PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation
July 21, 2021 08:00 ET
|
PharmaTher Holdings Ltd.
Strengthens position to become a leader in the intradermal delivery of FDA prescription-based ketamine productsSupports commercializing novel uses and delivery methods of psychedelics TORONTO, July ...
PharmaTher To Participate in Grizzle Psychedelics Con
June 28, 2021 08:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, June 28, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that...
PharmaTher To Present At The H.C. Wainwright Psychedelics In Psychiatry And Beyond Virtual Conference
June 16, 2021 08:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, June 16, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that...
PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression
June 15, 2021 08:00 ET
|
PharmaTher Holdings Ltd.
Potential for FDA 505(b)(2) regulatory pathway approval and FDA Fast Track designationAdvancing Ketamine and KETABET™ alone or in a microneedle patch for intradermal administrationPotential next...
PharmaTher Provides Research and Development Update and Milestones for 2021
June 10, 2021 08:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to provide...
PharmaTher and TSRL Enter into Co-Development Agreement For Microneedle Patch Delivery Technology for Psychedelics and Antivirals
June 01, 2021 08:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, June 01, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company and TSRL, Inc. (“TSRL”),...
PharmaTher Collaborates with MediSynergics to Develop Patented Ketamine Formulation for Pain Disorders and to Discover Novel Psychedelic Formulations
May 27, 2021 08:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, May 27, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce...
PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease
May 25, 2021 08:05 ET
|
PharmaTher Holdings Ltd.
TORONTO, May 25, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce...
Accomplished Clinical Researcher Matthew Macaluso Joins as Scientific and Clinical Advisor for PharmaTher’s Ketamine Programs
May 20, 2021 09:28 ET
|
PharmaTher Holdings Ltd.
TORONTO, May 20, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM) (OTCQB: PHRRF), a psychedelics biotech company, is pleased to announce the appointment...